Morgan Stanley analyst Judah Frommer raised the firm’s price target on Regenxbio (RGNX) to $24 from $22 and keeps an Overweight rating on the shares. The BLA for RGX-121 has been submitted, notes the analyst, who thinks Regenxbio remains in a “strong position” to commercialize RGX-121 and complete pivotal readouts for RGX-314 and RGX-202.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- RegenXBio: Strong Buy Rating Backed by Clinical Progress and Solid Financial Position
- REGENXBIO Reports Progress in Gene Therapy Pipeline
- Regenxbio reports Q4 EPS ($1.01), consensus ($1.08)
- RegenXBio: Positioned for Success in Gene Therapy Market with Strategic Partnerships and Strong Financials
- RegenXBio Partners with Nippon Shinyaku for Gene Therapies
Questions or Comments about the article? Write to editor@tipranks.com